Apply to the TCR Antigen Map Project

The goal of the Antigen Map project is to identify disease‑associated TCR sequences and repertoire features to build a new class of immune‑based diagnostics. In order to do so, we need your help to feed our machine learning algorithms with samples. These sequences will be used in the development of blood‑based diagnostics in:

  • type 1 diabetes
  • celiac disease
  • ovarian cancer
  • pancreatic cancer
  • other diseases with unmet need for a blood-based diagnostics


Detail your samples in the application below

The immunoSEQ hsTCRB data for all samples sequenced under the Antigen Map project will be returned to your immunoSEQ Analyzer workspace, your data will not be shared with other investigators participating in the project. The sequencing will be performed by Adaptive in our Service Lab at no charge to you.


Submission Standards

  • Samples should be at diagnosis or when there is some burden of disease
  • Blood (2mL or 15μg DNA) or PBMC (1 million cells or 5μg DNA)
  • Matched tissue will be considered in some disease states
  • Matched controls where available



  • immunoSEQ hsTCRB data are yours to analyze and to publish
  • Adaptive retains the rights to analyze the samples in conjunction with other samples received under the antigen map project

For more information, contact

Terms Agreement

A signed Terms Agreement is required before we can move forward post your application approval.
Once your application has been formally approved, you will be required to enter into an agreement before proceeding.



  1. Download and review the terms
  2. Indicate your agreement to the terms and provide your contact information
  3. We will send you final version by DocuSign

Application Form

Fill out the application below to submit you samples for approval. Once approved our team will reach out to you with next steps.



This Adaptive Antigen Map Samples for Free Sequencing Agreement (this “Agreement“) is made effective as of January 01, 2019 (the “Effective Date”), by and between InstitutionFullLegalName, a InstitutionEntityType formed under the laws of InstitutionIncorporationJurisdictionwith principal business offices at InstitutionAddress (hereinafter “Institution”) and Adaptive Biotechnologies Corporation, a Washington corporation with principal business offices at 1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102 (hereinafter “Adaptive” and with Institution, the “Parties”).


Institution possesses certain Materials and related confidential information provided in writing and marked as “Confidential” (“Information”), both as further defined below. Adaptive has developed a proprietary technology platform (ImmunoSEQ®) that enables high-throughput sequencing of T- and B-cell receptor genes to comprehensively assess the diversity and other characteristics of the immune system. The purpose of this Agreement is to facilitate the transfer of the Material and Information to Adaptive for analysis on such platform as well as collaborative research by both Parties with respect thereto, all as set forth in greater detail below (the “Research”). The immunosequencing data are the “Research Results” or “Results”.


1. Research. (a) The Research will consist of Adaptive performing Human TCRβ immunoSEQ analysis of Materials provided by Institution in accordance with this Agreement. Institution will supply to Adaptive biological samples (the “Materials”) and related Information (including sample metadata, which must be provided within ninety (90) days of sample receipt), but excluding personal health information (PHI) and excluding personal data (as that term is defined in the EU GDPR). Adaptive will perform the Research at no charge. Institution acknowledges and represents that the work is a fair market value exchange of value and that nothing in this Agreement is for the purpose of inducing the use or referral of any Adaptive product or service in violation of any applicable law.

(b) Institution represents and warrants to Adaptive that (i) Institution has the right to provide the Materials and Information to Adaptive for all uses contemplated by this Agreement, and (ii) proper informed consent has been obtained for the transfer of the Materials and Information for the Research, as necessary, including documented approvals of patients or any Institution review board as may be required by applicable law, regulation or best practice. Institution agrees to provide copies of all such documentation promptly upon a reasonable request from Adaptive and at Adaptive’s reasonable sole expense, provided that any patient identifiable data shall be removed or redacted from such copies.

(c) Institution will provide to Adaptive Materials for use in performing the activities described in this Agreement, together with any related information on a sample manifest as required by Adaptive to carry out the Research. The number and types of samples provided to Adaptive must meet program requirements at
tcrantigenmap, and all required metadata provided, in advance of Adaptive performing immunosequencing. The parties agree that Adaptive has the right and authorization to update its program requirements from time to time without notice or consent and that Institution may review updated requirements by proceeding to the foregoing link. Notwithstanding any provision in this Agreement, Metadata will not be provided that violates section 5 of this Agreement.

2. Background Technology. The term “Technology” means any information, process, machine, article of manufacture, composition of matter, concepts, and methods. All Technology and associated intellectual property rights (including improvements and derivative works) which are (a) existing as of the effective date of the Agreement and owned or controlled by either Party; or (b) independently developed by a Party Agreement shall be considered “Background Technology” which, as to Adaptive, includes but is not limited to, its immunosequencing assays, compositions, algorithms, inputs [e.g., data, receptor structures and profiles], computational models, and associated know-how. Background Technology will remain the exclusive property of the Party who owned or acquired rights to such Background Technology in the first place. No rights are granted by either Party to its Background Technology except as provided under the limited licenses expressly set forth herein. Neither Party will attempt to reverse engineer, characterize, or otherwise ascertain the components of either Party’s Background Technology.

3. Inventions. “Invention” means any invention or discovery that is conceived and reduced to practice in the course of performing the Research and is or may be patentable or otherwise protectable under Title 35 of the United States Code. Inventorship with respect to any Inventions will be determined according to United States patent law, as administered by the United States Patent & Trademark Office, and ownership shall follow inventorship.

4. Other Ownership.

(a) Except as provided in this Agreement, Institution retains title and all rights to the Materials and Information.

(b) All right, title and interest in, to and under the Research Results will be jointly owned by the Parties, and each Party may enjoy all rights and privileges accorded ownership of such Research Results without accounting or obligation to the other or the need to acquire any grant of license or other right from the other. For clarity, each Party shall have the full right to utilize the Research Results, which shall include without limitation, the right to conduct research and development activities, regulatory purposes, and to commercialize same and/or include such Research Results in products for commercial use.

5. Patient Identity. Institution represents and warrants that any information revealing the identity of the patients contributing the samples sent as Material will be removed, and Institution will not provide Adaptive any (1) Personal Data or Information as that term may be defined in Directive 95/46/EC, any national regulation of any Member States of the European Union implementing said Directive 95/46/EC, any EU law or regulation that may replace it, such as the General Data Protection Regulation (EU) 2016/679, and as the case may be any other applicable law or regulation relating to the protection of Personal Data (collectively “EU Data Protection Laws”), or (2) any Protected Health Information as that term may be defined in the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). Institution further covenants that any data or Information or Materials that it provides Adaptive will be de-identified, with respect to any identified or identifiable natural person as those terms are defined or interpreted pursuant to EU Data Protection Laws and HIPAA.

6. For Research Use Only; Not for Diagnostic Use. In no event will Institution use the data and results provided by Adaptive hereunder for diagnosing or otherwise informing treatment decisions for the individual patients from which the samples were derived.

7. Compliance. Institution represents and warrants that it will comply with any and all laws and regulations associated with its performance under this Agreement. Institution agrees to defend, indemnify, and hold Adaptive harmless from any and all liability, claims, cost and expense arising out of and to the extent of a breach of Institutions representation and warranty section 1, 5, or 7 of this Agreement.

8. Adaptive Deliverables. All processed sequence data from the assay of the Materials will be made available to Institution in a structured text format (for example, *.TSV) through the immunoSEQ Analyzer software platform for download and/or analysis.

9. Return of Materials. Upon termination or expiration of this Agreement or upon the earlier written request of Institution, Adaptive shall promptly destroy the remaining Materials in an approved manner, or return to Institution upon Institution’s written request.

10. No Warranty. Each Party acknowledges that the Materials and the Research Results are experimental in nature and that, except as expressly set forth in this Agreement, they are provided by each party WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED.

11. Termination. This Agreement will terminate on the earlier of the 3rd anniversary of the Effective Date, or upon thirty (30) days’ prior written notice of one Party to the other. The following provisions will survive termination or expiration of this Agreement in accordance with their terms: Sections 2, 3, 4, 6, 7, 9 and 11.

12. Miscellaneous. This Agreement may not be assigned by Adaptive without the prior written consent of Institution; provided, however, that Adaptive may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business or assets related to this Agreement, or in the event of its merger, consolidation, change in control or other similar transaction. The Agreement in its construction, validity, and performance shall be governed in all respects by the laws of the State of Washington without giving effect to the choice of law principles thereof. Both parties expressly agree that King County, Washington, USA shall be the exclusive venue for any and all disputes arising out of this Agreement. This Agreement sets forth the entire understanding between the Parties and the provisions hereof cannot be waived or amended except by written agreement executed by the Parties. This Agreement may be executed in multiple counterparts and delivered by facsimile, emailed PDF or other electronic means, each of which will be deemed an original, but all of which together will constitute one and the same instrument. All notices given hereunder shall be sent by certified mail, express delivery service such as Federal Express or shall be personally delivered to the applicable address listed at the beginning of this Agreement.


IN WITNESS THEREOF, Institution and Adaptive have caused this Collaborative Research Agreement to be executed by their respective duly authorized officers. This Agreement is only valid upon authorized signature by both parties and both parties represent their respective signatories are authorized.



[contact-form-7 id="4243" title="Antigen agreement form popup"]